These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 6125279)

  • 1. Effect of radioiodine on stimulatory activity of Graves' immunoglobulins.
    Atkinson S; McGregor AM; Kendall-Taylor P; Peterson MM; Smith BR
    Clin Endocrinol (Oxf); 1982 Jun; 16(6):537-43. PubMed ID: 6125279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term effects of radioiodine on thyrotrophin receptor antibodies in Graves' disease.
    Aizawa Y; Yoshida K; Kaise N; Kaise K; Fukazawa H; Kiso Y; Mori K; Sayama N; Kikuchi K; Abe K
    Clin Endocrinol (Oxf); 1995 May; 42(5):517-22. PubMed ID: 7621571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunoglobulins of untreated Graves' patients with or without thyrotropin receptor antibody (determined by porcine thyrocytes) universally elicit potent thyroid hormone-releasing activity in cultured human thyroid follicles.
    Sato K; Yamazaki K; Yamada E; Kanaji Y; Miura M; Obara T
    Thyroid; 1999 Oct; 9(10):979-88. PubMed ID: 10560951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunological findings and thyroid function of untreated Graves' disease patients with undetectable TSH-binding inhibitor immunoglobulin.
    Mukuta T; Tamai H; Oshima A; Morita T; Matsubayashi S; Fukata S; Kuma K
    Clin Endocrinol (Oxf); 1994 Feb; 40(2):215-9. PubMed ID: 7907955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical studies on abnormal thyroid stimulators in patients with Graves' disease. II. Clinical significance of measuring TSAb and TBII in patients with euthyroid Graves' disease and patients with hyperthyroid Graves' disease during antithyroid drug treatment].
    Uno C; Nishikawa M
    Nihon Naibunpi Gakkai Zasshi; 1988 Mar; 64(3):206-15. PubMed ID: 2456230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The relationship between serum thyroid autoantibodies, iodine intake, development and prognosis of Graves' disease].
    Chen W; Man N; Li YS; Shan ZY; Teng WP
    Zhonghua Nei Ke Za Zhi; 2006 Feb; 45(2):95-9. PubMed ID: 16624113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical value of a new TSH binding inihibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves' disease. Comparison with thyroid stimulating antibody bioassay.
    Maugendre D; Massart C
    Clin Endocrinol (Oxf); 2001 Jan; 54(1):89-96. PubMed ID: 11167931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical results of anti-inflammatory therapy in Graves' ophthalmopathy and association with thyroidal autoantibodies.
    Eckstein AK; Plicht M; Lax H; Hirche H; Quadbeck B; Mann K; Steuhl KP; Esser J; Morgenthaler NG
    Clin Endocrinol (Oxf); 2004 Nov; 61(5):612-8. PubMed ID: 15521965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Remission of Graves' hyperthyroidism predicted by smooth decreases of thyroid-stimulating antibody and thyrotropin-binding inhibitor immunoglobulin during antithyroid drug treatment.
    Takasu N; Yamashiro K; Komiya I; Ochi Y; Sato Y; Nagata A
    Thyroid; 2000 Oct; 10(10):891-6. PubMed ID: 11081255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thyroid-stimulating antibody and TSH-binding inhibitor immunoglobulin in 277 Graves' patients and in 686 normal subjects.
    Takasu N; Oshiro C; Akamine H; Komiya I; Nagata A; Sato Y; Yoshimura H; Ito K
    J Endocrinol Invest; 1997 Sep; 20(8):452-61. PubMed ID: 9364248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serial changes in thyroid-stimulating antibody and thyrotropin binding inhibitor immunoglobulin at the time of postpartum occurrence of thyrotoxicosis in Graves' disease.
    Tamaki H; Amino N; Aozasa M; Mori M; Tanizawa O; Miyai K
    J Clin Endocrinol Metab; 1987 Aug; 65(2):324-30. PubMed ID: 2885336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical studies on abnormal thyroid stimulators in patients with Graves' disease. I. A sensitive assay for thyroid-stimulating antibodies using cultured porcine thyroid cells and polyethylene glycol precipitation of serum].
    Uno C; Nishikawa M
    Nihon Naibunpi Gakkai Zasshi; 1988 Mar; 64(3):193-205. PubMed ID: 2899523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of thyroid stimulating activities measured by cyclic AMP production, those by radioiodine uptake in FRTL-5 cells and TSH-binding inhibitory activities in patients with hyperthyroid and euthyroid Graves' diseases.
    Kasagi K; Hatabu H; Tokuda Y; Arai K; Iida Y; Konishi J
    Acta Endocrinol (Copenh); 1988 Mar; 117(3):365-72. PubMed ID: 2898192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relationships between serum T3 index, thyroid volume, and thyroid stimulating, TSH receptor binding and thyroid growth stimulating antibodies in untreated Graves' disease.
    Bliddal H; Hegedüs L; Hansen JM; Bech K; van der Gaag R; Drexhage HA
    Clin Endocrinol (Oxf); 1987 Jul; 27(1):75-84. PubMed ID: 2888551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specific effects of radioiodine treatment on TSAb and TBAb levels in patients with Graves' disease.
    Michelangeli VP; Poon C; Topliss DJ; Colman PG
    Thyroid; 1995 Jun; 5(3):171-6. PubMed ID: 7580264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of TSH receptor antibody by 'natural in vivo human assay' in neonates born to mothers with Graves' disease.
    Tamaki H; Amino N; Iwatani Y; Tachi J; Kimura M; Mitsuda N; Ichihara K; Tanizawa O; Miyai K
    Clin Endocrinol (Oxf); 1989 May; 30(5):493-503. PubMed ID: 2575017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of thyroid stimulating antibodies and TSH-binding inhibiting immunoglobulins in the follow-up of Graves' disease.
    Hörmann R; Saller B; Müller R; Mann K
    Klin Wochenschr; 1985 Dec; 63(24):1247-52. PubMed ID: 2868149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of subtotal thyroidectomy with propranolol preparation on antibody activity in Graves' disease.
    Steel NR; Taylor JJ; Young ET; Farndon JR; Holcombe M; Kendall-Taylor P
    Clin Endocrinol (Oxf); 1987 Jan; 26(1):97-106. PubMed ID: 3802553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison between thyroid stimulating and tsh-binding inhibiting immunoglobulins of Graves' disease.
    Macchia E; Fenzi GF; Monzani F; Lippi F; Vitti P; Grasso L; Bartalena L; Baschieri L; Pinchera A
    Clin Endocrinol (Oxf); 1981 Aug; 15(2):175-82. PubMed ID: 6118213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic value of parallel measurements of thyrotropin binding inhibiting immunoglobulins (TBII) and thyroid adenylate cyclase stimulating antibodies (TSAb) in Graves' disease after longterm antithyroid treatment.
    Bliddal H; Bech K; Siersbaek-Nielsen K; Friis T
    J Endocrinol Invest; 1983 Aug; 6(4):259-62. PubMed ID: 6139399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.